Abstract P2-12-22: A multicenter, single-arm, phase II clinical trial of oral CDK4/6 inhibitor darciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive, HER2-negative female breast cancer
Lists
Only you see this
Abstract
Abstract Background: Although the role of endocrine therapy in the adjuvant treatment of HR+/HER2- breast cancer has been established, Early HR positive and HER2 negative breast cancer show a long-term risk of recurrence. Studies have shown that about 20% of patients experience recurrence and metastasis after receiving adjuvant endocrine therapy for 5 years. CDK4/6 inhibitor combined with endocrine therapy for HR+/HER2- breast cancer has been proven to have synergistic effects. Previous studies have shown that Abemaciclib and ribociclib can reduce the risk of recurrence and increase iDFS in early high-risk HR positive breast cancer, but conventional doses lead to excessive adverse events and patients interrupt treatment. Compared with different CDK4/6 inhibitors combined with AI as first-line treatment of advanced HR+ breast cancer, dalpiciclib achieved the highest ORR. It was found that dose reduction had no significant identifiable negative impact on the progression-free survival evaluated in the study. This study will be evaluated the effectiveness and safety of a small-dose dalpiciclib combined with endocrine therapy in hormone receptor-positive, HER2-negative breast cancer in women. Methods: This multicenter, single arm, phase II clinical trial(ChiCTR2400080962) will enroll 317 women with hormone receptor-positive early breast cancer from Jan 2024 to Dec 2025. Eligible patients are aged ≥18 years and ≤75 years, either postmenopausal or pre/perimenopausal. Histologically confirmed stage II-III (a) ⅡA-N0: Grade 2 with high risk [Ki67≥20% or high-risk gene characteristics], Grade 3, N1; (b) Anatomical stage ⅡB: N0 or N1; (c) Anatomical stage Ⅲ: N0, N1, N2, or N3. HR positive defined as ER positive: Positive staining tumor cells accounting for ≥10% of all tumor cells (confirmed by the pathology department of the research center), regardless of PR expression status. Patients will receive dalpiciclib 100mg daily for 21 days followed by a 7-day break( every 28 days as a cycle) for 3 years. All patients receive standard endocrine therapy for 5-10 years after standard postoperative adjuvant chemotherapy and/or adjuvant radiotherapy. The primary endpoint is Intermediate Disease-Free Survival(IDFS), while the secondary endpoints including Disease-Free Survival(DFS), Distant Disease-Free Survival(DDFS),Overall Survival(OS).The safety of patients will be assessed by the quality of life rating scale (EORTIC QLQ-C30). Conclusions: This multicenter, single-arm, phase II clinical trial will provide valuable insight into the efficacy and safety of a small-dose dalpiciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive, HER2-negative female breast cancer. If proven effective and well-tolerated, this regimen may offer a more convenient treatment option for this patient population, potentially improving quality of life and treatment adherence. Citation Format: Jie Ouyang, Yifen Wu, Pengfei Qian, Jinsong He, Hao Hu, Shi Tang, Qing Zhang, Heng Huang, Shuqin Xie, Zhuohong Liang, Ailing Zhang, Hong Hu, Xiaobo Wu, Heng Tian, Ying Cao, Yongxia Wang, Zhibiao Zhang, Yufang He, Ting Yang. A multicenter, single-arm, phase II clinical trial of oral CDK4/6 inhibitor darciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive, HER2-negative female breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P2-12-22.
BibTeX
@inproceedings{ouyang2025abstract,
author = {Jie Ouyang and Yifeng Wu and Pengfei Qian and Jinsong He and Hao Hu and Shi Tang and Qing Zhang and Heng Huang and Shuqin Xie and Zhuo-hong Liang and Ailing Zhang and Hong Hu and Xiaohua Wu and Heng Tian and Ying Cao and Yong‐Xia Wang and Zhibiao Zhang and Yufang He and Ting Yang},
title = {{Abstract P2-12-22: A multicenter, single-arm, phase II clinical trial of oral CDK4/6 inhibitor darciclib in combination with endocrine therapy in adjuvant treatment for hormone receptor-positive, HER2-negative female breast cancer}},
booktitle = {Clinical},
year = {2025},
doi = {10.1158/1557-3265.sabcs24-p2-12-22},
}Loading related content...